Slaughter and May advised DiaSorin S.p.A. on its USD 1.6bn financing package for its acquisition of Luminex Corporation

Slaughter and May advised DiaSorin S.p.A., a global leader in the laboratory diagnostics market, specializing in immunodiagnostics and molecular diagnostics, on the USD 1.6bn bank financing package for its recently announced acquisition of Luminex Corporation. The acquisition will, among other things, broaden DiaSorin’s positioning in the molecular diagnostics space and give DiaSorin access to Luminex’s molecular diagnostics multiplexing technology. The transaction is expected to close in the third quarter of 2021 and is subject to Luminex shareholder approval, satisfaction of antitrust and CFIUS regulatory requirements and other customary closing conditions.

The financing package comprises a USD 1.1bn term loan facility maturing in 2026 and a USD 500m bridge loan facility maturing in 2022 with an option (exercisable at DiaSorin’s discretion) to extend the maturity of the bridge loan facility by an additional 12 months. The facilities were arranged by the Bookrunners and Mandated Lead Arrangers Citibank, N.A., London Branch, BNP Paribas, Italian Branch, Mediobanca - Banca di Credito Finanziario S.p.A. and UniCredit S.p.A.

Slaughter and May worked as part of an integrated team with DiaSorin’s US legal advisors, Cravath Swaine & Moore LLP and, Italian legal advisors, Pedersoli Studio Legale.